Scenarios that move IBRX

ImmunityBio, Inc. - Common Stock

Scenarios that move IBRX: 1 analysis, 1 positive, 0 negative.

  1. · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▲ · impact +91 · confidence high · horizon immediate

All scenarios · Run a scenario · Pricing